

# REAL-WORLD EXPERIENCE WITH PROLONGED TEDIZOLID TREATMENT: EFFECTIVENESS AND SAFETY

J. Fernández-Fradejas<sup>1</sup>, E. Gemeno-López<sup>1</sup>, A. Díaz-Gago<sup>1</sup>, J. Sáez De La Fuente<sup>1</sup>, AM. Álvarez-Díaz<sup>1</sup>.  
<sup>1</sup>Hospital Universitario Ramón y Cajal, Pharmacy, Madrid, Spain.

## BACKGROUND AND IMPORTANCE

Tedizolid demonstrated to be effective and safe in clinical trials. However, evidence concerning its effectiveness and tolerability in long-term treatments is still scarce.

## AIM AND OBJECTIVES

To assess the use of tedizolid and its effectiveness and safety in long term treatments.

## MATERIAL AND METHODS

Observational and retrospective study (1 November 2018 - 31 May 2021)

### Inclusion criteria

- > 18 years-of-age.
- Tedizolid treatment for seven or more days

### Variables

- Collected from electronic medical record
- Demographic
  - Clinical
  - Safety

### Assessment of effectiveness



Clinical resolution of infection and absence of recurrence

### Assessment of safety



- Incidence of adverse drug events
- Changes in haemoglobin and platelet count

## RESULTS

### Demographics

- N = 39 patients
- 51% female
- Median age: 71 (IQR 52-76)

### Tedizolid treatment

- Median duration: 15 days (IQR 10-20)
- Previous linezolid: 30% (n=12)
- Main reason for tedizolid selection:
  - Drug-drug interactions (53,8%, n=21)
  - Previous cytopenia (43,5%, n=17)


### Safety outcomes

- No serious adverse drug events reported.
- Mean haemoglobin value unchanged (10.2 g/dL to 10.5 g/dL, p=0,18)
- Mean platelet count unchanged ( $243,9 \times 10^6/\text{mL}$  to  $243,7 \times 10^6/\text{mL}$ , p=0,98)
- Absence of serotoninergic syndrome in patients treated with serotoninergic drugs (n=21)


### Clinical outcomes

79,4% (n=27): favourable evolution, 20,6% (n=7): treatment failure  
Three patients were lost during follow-up period, two died of unrelated causes

### Treatment indication



### Most frequent isolates



## CONCLUSIONS AND RELEVANCE

In most cases, tedizolid was used for off-label indications. Our results suggest that tedizolid can be an effective and safe alternative in the management of diverse gram positive infections, even in prolonged treatments.